Division of Molecular and Cellular Biology, Toronto General Hospital Research Institute, Dept of Laboratory Medicine and Pathobiology, University of Toronto, Ontario, Canada.
Cancer Biol Ther. 2010 Sep 15;10(6):567-78. doi: 10.4161/cbt.10.6.12535. Epub 2010 Oct 1.
Multiple myeloma (MM) is an incurable plasma cell malignancy in which p53 is rarely mutated. Thus, activation of the p53 pathway by a small molecule inhibitor of the p53-MDM2 interaction, nutlin, in MM cells retaining wild type p53 is an attractive therapeutic strategy. Recently we reported that nutlin plus velcade (a proteasome inhibitor) displayed a synergistic response in MM. However, the mechanism of the p53-mediated apoptosis in MM has not been fully understood. Our data show that nutlin-induced apoptosis correlated with reduction in cell viability, upregulation of p53, p21 and MDM2 protein levels with a simultaneous increase in pro-apoptotic targets PUMA, Bax and Bak and downregulation of anti-apoptotic targets Bcl2 and survivin and activation of caspase in MM cells harboring wild type p53. Nutlin-induced apoptosis was inhibited when activation of caspase was blocked by the caspase inhibitor. Nutlin caused mitochondrial translocation of p53 where it binds with Bcl2, leading to cytochrome C release. Moreover, blocking the transcriptional arm of p53 by the p53-specific transcriptional inhibitor, pifithrin-α, not only inhibited nutlin-induced upregulation of p53-transcriptional targets but also augmented apoptosis in MM cells, suggesting an association of transcription-independent pathway of apoptosis. However, inhibitor of mitochondrial translocation of p53, PFT-μ, did not prevent nutlin-induced apoptosis, suggesting that the p53 transcription-dependent pathway was also operational in nutlin-induced apoptosis in MM. Our study provides the evidence that nutlin-induced apoptosis in MM cells is mediated by transcription-dependent and -independent pathways and supports further clinical evaluation of nutlin as a novel therapeutic agent in MM.
多发性骨髓瘤(MM)是一种无法治愈的浆细胞恶性肿瘤,其中 p53 很少发生突变。因此,小分子抑制剂 nutlin 通过抑制 p53-MDM2 相互作用来激活 p53 通路,在保留野生型 p53 的 MM 细胞中是一种有吸引力的治疗策略。最近我们报道,在 MM 中,nutlin 加硼替佐米(蛋白酶体抑制剂)显示出协同反应。然而,p53 介导的 MM 细胞凋亡的机制尚未完全理解。我们的数据表明,nutlin 诱导的凋亡与细胞活力降低、p53、p21 和 MDM2 蛋白水平上调、促凋亡靶点 PUMA、Bax 和 Bak 同时增加以及抗凋亡靶点 Bcl2 和 survivin 下调以及 caspase 在携带野生型 p53 的 MM 细胞中的激活相关。当 caspase 激活被 caspase 抑制剂阻断时,nutlin 诱导的凋亡被抑制。nutlin 导致 p53 在线粒体易位,与 Bcl2 结合,导致细胞色素 C 释放。此外,p53 特异性转录抑制剂 pifithrin-α 阻断 p53 的转录激活臂,不仅抑制了 nutlin 诱导的 p53 转录靶基因的上调,而且增强了 MM 细胞的凋亡,表明凋亡存在不依赖转录的途径。然而,p53 线粒体易位抑制剂 PFT-μ 并没有阻止 nutlin 诱导的凋亡,表明 nutlin 诱导的 MM 细胞凋亡中也存在 p53 转录依赖性途径。我们的研究提供了证据,表明 nutlin 诱导的 MM 细胞凋亡是通过转录依赖和非依赖途径介导的,并支持进一步临床评估 nutlin 作为 MM 的新型治疗剂。